These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35668930)

  • 1. Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity.
    Li L; Huang Z; Du K; Liu X; Li C; Wang D; Zhang Y; Wang C; Li J
    Front Pharmacol; 2022; 13():900699. PubMed ID: 35668930
    [No Abstract]   [Full Text] [Related]  

  • 2. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
    Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
    PeerJ; 2022; 10():e14432. PubMed ID: 36518297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C1QTNF6 is a Prognostic Biomarker and Related to Immune Infiltration and Drug Sensitivity: A Pan-Cancer Analysis.
    Liu W; Zhang J; Xie T; Huang X; Wang B; Tian Y; Yuan Y
    Front Pharmacol; 2022; 13():855485. PubMed ID: 35401204
    [No Abstract]   [Full Text] [Related]  

  • 4. Pan-Cancer Analyses Confirmed the Ferroptosis-Related Gene
    Lin Y; Dong Y; Liu W; Fan X; Sun Y
    Int J Gen Med; 2022; 15():2501-2513. PubMed ID: 35282646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3.
    Wu Y; Zhang B; Nong J; Rodrìguez RA; Guo W; Liu Y; Zhao S; Wei R
    Front Genet; 2023; 14():1045061. PubMed ID: 37035741
    [No Abstract]   [Full Text] [Related]  

  • 7. ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis.
    Ning Y; Li Y; Wang H
    Front Genet; 2023; 14():1108167. PubMed ID: 36713082
    [No Abstract]   [Full Text] [Related]  

  • 8. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
    Zhao C; Liu Y; Ju S; Wang X
    Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Pan-Cancer Analysis Confirmed That ATG5 Promoted the Maintenance of Tumor Metabolism and the Occurrence of Tumor Immune Escape.
    Xu C; Zang Y; Zhao Y; Cui W; Zhang H; Zhu Y; Xu M
    Front Oncol; 2021; 11():652211. PubMed ID: 33842365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Integrative Pan-Cancer Analysis Revealing LCN2 as an Oncogenic Immune Protein in Tumor Microenvironment.
    Xu WX; Zhang J; Hua YT; Yang SJ; Wang DD; Tang JH
    Front Oncol; 2020; 10():605097. PubMed ID: 33425761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Cancer Analysis Based on
    Zhang Y; Wang S; Han S; Feng Y
    Front Oncol; 2022; 12():844794. PubMed ID: 35359375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration.
    Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q
    Front Oncol; 2022; 12():998336. PubMed ID: 36185230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FCGR3A Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lower-Grade Glioma.
    Sun K; Fei X; Xu M; Xu R; Xu M
    J Oncol; 2022; 2022():9499317. PubMed ID: 39280892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
    Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
    Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Integrative Pan-Cancer Analysis of PBK in Human Tumors.
    Wen H; Chen Z; Li M; Huang Q; Deng Y; Zheng J; Xiong M; Wang P; Zhang W
    Front Mol Biosci; 2021; 8():755911. PubMed ID: 34859049
    [No Abstract]   [Full Text] [Related]  

  • 16. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
    Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
    Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy.
    Cui Z; Zou F; Wang R; Wang L; Cheng F; Wang L; Pan R; Guan X; Zheng N; Wang W
    World J Surg Oncol; 2023 Sep; 21(1):309. PubMed ID: 37759234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive pan-cancer analysis and experiments revealed R3HDM1 as a novel predictive biomarker for prognosis and immune therapy response.
    Liu J; Bing Z; Wang J
    Front Genet; 2024; 15():1404348. PubMed ID: 39376739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EF-Hand Domain-Containing Protein D2 (EFHD2) Correlates with Immune Infiltration and Predicts the Prognosis of Patients: A Pan-Cancer Analysis.
    Wang Y; Song M; Gao B
    Comput Math Methods Med; 2022; 2022():4878378. PubMed ID: 35341013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RecQ mediated genome instability 2 (
    Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
    Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.